Polynovo Limited · ASX:PNV
Polynovo — H1 FY2023 Earnings Presentation
11 slides from Polynovo's earnings presentation, Feb 23, 2023
Slide 1: 1H FY23 Results
PolyNovo 1H FY23 Results (in conjunction with Appendix 4D) Accelerating Global Impact 23 February 2023
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this pr
Slide 3: Accelerating Global Impact in 1H FY23
Accelerating Global Impact in 1H FY23 ~ 8K patients in first six months of 2023, versus ~ 10K patients through full year 2022 Strong global revenue, $29.5m, growing at 62.2% in 1H FY23 Global BTM product sales growing at 67.5% US revenue at $22.8m, growing at 61.0% ROW revenue at $4.5m, growing at 1
Slide 4: 1H FY23 Financial Results Review
1H FY23 Financial Results Review 4
Slide 5: Revenue Growth
Revenue Growth 62.2% 1H FY23 Total Revenue Customers (Hospitals) Employees $29.5m 515 173 41.9% 361 122 25.3% $18.2m 64.6% 295 91 99.7% $12.8m 229 $10.2m 65 $6.2m 123 41 $3.1m 1H18 1H19 1H20 1H21 1H22 1H23 1H19 1H20 1H21 1H22 1H23 1H19 1H20 1H21 1H22 1H23 • 1H21 and 1H22 impacted by Covid-19 • Total
Slide 6: 1H FY23 Financial Results
1H FY23 Financial Results Total Revenue ($m) 0.1 Regional Revenue ($m) 2.1 2.5 2.1 0.1 1.8 0.9 1.3 0.2 1.4 0.1 1.8 0.6 1.8 0.0 1.6 24.9 0.5 0.0 1.4 1.9 16.0 8.4 10.3 3.8 8.6 11.2 16.3 27.3 4.8 1H FY19 1H FY20 1H FY21 1H FY22 1H FY23 1H FY19 1H FY20 1H FY21 1H FY22 1H FY23 BTM Product Sales BARDA Con
Slide 7: 1H FY23 Financial Results
1H FY23 Financial Results Revenue, Opex, NLAT (excl. non-cash items) Operating Expenses ($m) (excl. non-cash items) 29.5 30.2 • Operating Expenses +59% • Continued investment in accelerating growth • Increase headcount from 152 (Jun ‘22) to 173 (Dec ’22) • Entered new markets, Canada, Hong Kong and
Slide 8: 1H FY23 Financial Results
1H FY23 Financial Results Net cash flow from operations ($m) Capex ($m) Cash on hand ($m) 0.0 3.5 50.5 (0.5) FY19 (1.0) 2.4 (1.5) (1.4) (2.0) (2.5) (2.2) (2.2) 7.7 0.2 0.2 3.3 (3.0) (2.7) (3.5) (3.3) 1H FY20 1H FY21 1H FY22 1H FY23 1H FY21 1H FY22 1H FY23 1H FY19 1H FY20 1H FY21 1H FY22 1H FY23 High
Slide 9: 1H FY23 Financial Results
1H FY23 Financial Results ($m) 1H FY23 1H FY22 Change % P&L Highlights Revenue (Excl. Interest) 29.4 18.2 61.8% Expenses Changes in inventories & WIP (1.6) (0.9) 85.8% • Product sales +67.5% Employee-related expenses * (17.7) (7.6) 131.5% * R&D Costs (3.0) (2.4) 27.8% Corp, administrative & overhead
Slide 10: Accelerating Global Impact
Accelerating Global Impact Uniquely situated to drive global growth • Genius technology • Underserved market • Capital efficient Growth and Scaling Our near term results could be lumpy with consistent long-term growth trajectory • As we add indications beyond burns, and enter new geographies Purpose
Slide 11: Slide 11